Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page


Press Releases

Press Releases
  Date Title and Summary View
Sep 13, 2005
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Sept. 13, 2005–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today a co-exclusive license agreement with Stanford University related to the discovery and development of therapeutic products for hepatitis C virus (HCV) ...
Oct 19, 2004
Intellectual Property From Max Planck Society Strengthens Companies’ Leadership Positions In RNA-Based Drug Discovery and Development CAMBRIDGE, Mass., and CARLSBAD, Calif., Oct. 19 /PRNewswire-FirstCall/ — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Isis Pharmaceuticals, Inc. ...
Page: FirstPrevious ...
= add release to Briefcase